Acrongenomics Retains KGMC Group
News Nov 10, 2005
KGMC Group LLC will work with Acrongenomics to complete formal validations of the advanced Nano-JETA™ platform, secure publications of this technology in respected medical and scientific journals and identify ideal partners to commercialize the technology.
“Following a year of thorough study, our scientists and Board of Directors have confirmed that Acrongenomics' know-how in nanotechnology has resulted in compelling breakthroughs, significantly impacting our battle with various diseases such as cancer,” Says KGMC Group President Bill Kanatas.
“We are convinced that Nano-JETA™ technology platform can accelerate and enhance the commonly used Real Time PCR amplification process, so that it is rendered 100% accurate in detecting genetic diseases such as cancer.”
“Neo-EpCAM™ cancer detection assay is the first application utilizing the Nano-JETA™ technology.”
“More so exciting is that the process takes less than two minutes. Because it is fast, inexpensive, easy to administer, non-invasive, accurate, specific and uses existing equipment, we are convinced that the technology will assist physicians in detecting genetic diseases quickly, accurately and early enough to potentially save lives and avoid much cost and anguish.”
“Now confident in the technology, we will assist Acrongenomics in securing a partner to further develop and market such technology.”
Previous work by the International Multiple Sclerosis Genetics Consortium (IMSGC) has identified 233 genetic risk variants. However, these only account for about 20% of overall disease risk, with the remaining genetic culprits proving elusive. A new study has tracked down four of these hard-to-find genes.READ MORE